

# 1 Sex-based differences in clearance of chronic *Plasmodium* 2 *falciparum* infection

3  
4 Jessica Briggs, M.D.<sup>1\*</sup>, Noam Teyssier, B.S.<sup>1</sup>, Joaniter I. Nankabirwa, Ph.D.<sup>2,3</sup>, John Rek, MSc<sup>2</sup>,  
5 Prasanna Jagannathan, M.D.<sup>4</sup>, Emmanuel Arinatiwe, MPH<sup>2,9</sup>, Teun Bousema, Ph.D.<sup>5,6</sup>, Chris  
6 Drakeley, Ph.D.<sup>6</sup>, Margaret Murray, M.S.<sup>4</sup>, Emily Crawford, Ph.D.<sup>7</sup>, Nicholas Hathaway, M.D.<sup>8</sup>,  
7 Sarah G. Staedke, Ph.D.<sup>9</sup>, David Smith, Ph.D.<sup>10</sup>, Phillip J. Rosenthal, M.D.<sup>1</sup>, Moses Kanya,  
8 Ph.D.<sup>2,3</sup>, Grant Dorsey, M.D.<sup>1</sup>, Isabel Rodriguez-Barraquer, M.D.<sup>1\*\*</sup>,  
9 Bryan Greenhouse, M.D.<sup>1\*\*</sup>

10 **\*\*co-senior authors**

11  
12 <sup>1</sup> Department of Medicine, University of California San Francisco, San Francisco, CA  
13 <sup>2</sup> Infectious Diseases Research Collaboration, Kampala, Uganda  
14 <sup>3</sup> Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda  
15 <sup>4</sup> Department of Medicine, Stanford University, Palo Alto, CA  
16 <sup>5</sup> Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen,  
17 the Netherlands  
18 <sup>6</sup> Department of Immunology and Infection, London School of Hygiene and Tropical Medicine,  
19 London, UK  
20 <sup>7</sup> Chan-Zuckerberg Biohub, San Francisco, CA  
21 <sup>8</sup> Department of Medicine, University of Massachusetts, Amherst, MA  
22 <sup>9</sup> Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK  
23 <sup>10</sup> Institute for Health Metrics & Evaluation, University of Washington, Seattle, WA  
24  
25  
26  
27

28  
29 **\*Corresponding Author:** Jessica Briggs, Rm 525 Building 3, Zuckerberg San Francisco  
30 General Hospital, San Francisco, CA. Email: [jessica.briggs@ucsf.edu](mailto:jessica.briggs@ucsf.edu)  
31

32 **Author Contributions:** M.K, G.D., I.R-B., P.J., and B.G designed and lead the project. J.B.  
33 performed experiments, analyzed the sequencing data, performed statistical analyses, and  
34 drafted the paper. N.T. was responsible for bioinformatics programming and data analysis.  
35 J.I.N., J.R, and E.A. led the parent study in Uganda. E.C. and N.H. provided technical support  
36 for sequencing and bioinformatics analysis. M.M., C.D., T.B., S.G.S, D.S., and P.J.R. edited the  
37 manuscript.

38 **Key words:** malaria, asymptomatic infection, force of infection, duration of infection,  
39 genotyping, sex-based differences

## 40 Abstract

41

42 **Background:** Multiple studies have reported a higher prevalence of malaria infection in males  
43 compared to females. However, it remains unknown whether this is due to differences in  
44 behavioral factors or biological sex playing a direct role in the host response to the malaria  
45 parasite.

46 **Methods and Findings:** To test the hypothesis that sex-based differences in host-parasite  
47 interactions affect the epidemiology of malaria, we intensively followed a cohort of individuals  
48 living in a malaria endemic area of eastern Uganda. By performing frequent sampling,  
49 ultrasensitive quantitative PCR (qPCR), and amplicon deep sequencing, we followed *P.*  
50 *falciparum* infections over time to estimate both force of infection (FOI) and rate of clearance by  
51 sex. Prevalence of malaria infection by qPCR was 14.4% in males versus 9.2% in females  
52 (difference 5.2%, 95% confidence interval [CI] 3.8% to 6.5%). There was no evidence of  
53 differences in behavioral risk factors, incidence of malaria, or FOI by sex. In contrast, females  
54 cleared asymptomatic infections at a faster rate than males (hazard ratio [HR] = 1.82, 95% CI  
55 1.20 to 2.75 by clone and HR = 2.07, 95% CI 1.24 to 3.47 by infection event) in multivariate  
56 models adjusted for age, timing of infection onset, and parasite density.

57 **Conclusions:** In this study, differences in *P. falciparum* prevalence between males and females  
58 observed in endemic settings were driven by faster clearance rates in females and not by  
59 increased infection rates in males. These findings implicate biological sex-based differences as  
60 an important factor in the host response to this globally important pathogen.

61

62

## 63 Introduction

64 Chronic infection with *Plasmodium falciparum*, the most common and fatal malaria  
65 parasite, can lead to morbidity for those infected and contribute to ongoing transmission<sup>1–</sup>  
66 4. Multiple studies performed in different contexts have demonstrated that, excepting impacts of  
67 pregnancy, a greater proportion of males than females in endemic settings carry malaria  
68 parasites in their blood<sup>5–7</sup>. It has often been postulated that these differences in parasite  
69 prevalence stem from an increased risk of males acquiring infection due to socio-behavioral  
70 factors<sup>6,8–10</sup>. However, biological sex itself has been demonstrated to affect responses to other  
71 pathogens, and thus an alternative hypothesis is that the sexes have different responses to the  
72 malaria parasite once infected<sup>11–14</sup>.

73 Estimating the host response to *P. falciparum* infection requires close follow up of  
74 infected individuals, sensitive detection of parasites, and the ability to distinguish superinfection,  
75 which is common in endemic areas, from persistent infection. To test the hypothesis that sex-  
76 based differences in host-parasite interactions affect the epidemiology of malaria, we intensively  
77 followed a representative cohort of individuals living in a malaria endemic area of eastern  
78 Uganda. By performing frequent sampling, ultrasensitive qPCR, and amplicon deep sequencing,  
79 we were able to accurately detect the onset of new infections and follow them over time to  
80 estimate their duration. Using these data, we show that females cleared their infections more  
81 rapidly than males, implicating biological sex-based differences as important in the host  
82 response to this globally important pathogen.

## 83 Methods

### 84 Study setting and population-level malaria control interventions

85 This cohort study was carried out in Nagongera sub-county, Tororo district, eastern

86 Uganda. Nagongera district is historically a high malaria transmission area; however, 7 rounds  
87 of indoor residual spraying (IRS) from 2014-2019 have resulted in a significant decline in the  
88 burden of malaria as previously described<sup>15</sup>.

89

## 90 **Study design, enrollment, and follow-up**

91 All members of 80 randomly selected households with at least two children were  
92 enrolled in October 2017 using a list generated by enumerating and mapping all households in  
93 Nagongera sub-county. The cohort was dynamic such that residents joining the household were  
94 enrolled and residents leaving the household were withdrawn. Data for this analysis was  
95 collected from October 1st, 2017 through March 31st, 2019. Participants were followed at a  
96 designated study clinic open daily from 8 AM to 5 PM. Participants were encouraged to seek all  
97 medical care at the study clinic and avoid the use of antimalarial medications outside of the  
98 study. Routine visits were conducted every 28 days and included a standardized clinical  
99 evaluation, assessment of overnight travel outside of Nagongera sub-county, and collection of  
100 blood by phlebotomy for detection of malaria parasites by microscopy and molecular studies.  
101 Participants with fever ( $>38.0^{\circ}\text{C}$  tympanic) or history of fever in the previous 24 hours had a  
102 thick blood smear read urgently. If the smear was positive, the patient was diagnosed with  
103 malaria and treated with artemether-lumefantrine. Study participants were visited at home every  
104 2 weeks to assess use of long-lasting insecticidal nets (LLINs) the previous night.

105

## 106 **Laboratory methods**

107 Blood smears were performed as previously described<sup>15</sup>. For qPCR and genotyping, we  
108 collected 200  $\mu\text{L}$  of blood at enrollment, at each routine visit, and at the time of malaria  
109 diagnosis. DNA was extracted using the PureLink Genomic DNA Mini Kit (Invitrogen) and  
110 parasitemia measured using an ultrasensitive qPCR assay<sup>16</sup>. Samples with a parasite density  
111  $\geq 0.1$  parasites/ $\mu\text{L}$  blood were genotyped via amplicon deep-sequencing. All samples positive

112 for asexual parasites by microscopy but negative for *P. falciparum* by qPCR were tested for the  
113 presence of non-falciparum species using nested PCR.<sup>17</sup>

114

#### 115 *Sequencing library preparation*

116 Hemi-nested PCR was used to amplify a 236 base-pair segment of apical membrane  
117 antigen 1 (AMA-1) using a published protocol<sup>18</sup>, with modifications (**Supplemental Appendix**).  
118 Samples were amplified in duplicate, indexed, pooled, and purified by bead cleaning.  
119 Sequencing was performed on an Illumina MiSeq platform (250bp paired-end).

120

#### 121 **Bioinformatics methods**

122 Data extraction, processing, and haplotype clustering were performed using SeekDeep<sup>19</sup>,  
123 followed by additional filtering<sup>20</sup>. **Supplemental Figure 1** shows the full bioinformatics  
124 workflow.

125

#### 126 **Data analysis**

127 A clone was defined as a genetically identical group of parasites. A baseline infection  
128 was defined as an infection detected in the first 60 days of observation. New infections were  
129 defined as a new clone or group of clones detected in an individual after day 60. To account for  
130 the fact that a clone might be missed in a single sample due to fluctuations in parasite density<sup>21–</sup>  
131 <sup>24</sup>, we allowed 3 “skips” in detection and classified an infection as cleared only if it was not  
132 identified in 4 contiguous samples from routine visits. Additional details are found in

#### 133 **Supplemental Table 1.**

134 Because polyclonal infections can occur due to co-infection (one mosquito bite  
135 transmitting multiple clones) or superinfection (multiple bites), we analyzed the data both by  
136 clone and by infection event. For analysis by clone, the appearance of each unique clone was  
137 counted as a new infection and disappearance as a clearance event. For analysis by infection

138 event, any new clones seen within 3 visits of the date of the first newly detected clone(s) were  
139 grouped together and considered one new “infection event.” Clearance of infection for these  
140 events required that all clones in the group be absent for 4 routine visits.

141 Data analysis was conducted in R<sup>25</sup> and Python<sup>26</sup>. Comparisons of proportions were  
142 made using Poisson regression with generalized estimating equations to adjust for repeated  
143 measures. Comparison of parasite density by sex was made using linear regression with  
144 generalized estimating equations to adjust for repeated measures. Force of infection (FOI) was  
145 calculated by dividing the number of new infections, including malaria episodes, by person time.  
146 Comparisons of incidence measures were made using negative binomial regression. Hazards  
147 for clearance of untreated, asymptomatic infections were estimated using time-to-event models  
148 (shared frailty models fit using R package “frailtypack,” version 2.12.2)<sup>27,28</sup>. These models  
149 assumed a constant hazard of clearance and included random effects to account for repeated  
150 measures in individuals. Parasite density was included in the model as a time-varying covariate.  
151 Duration of infection in days was calculated as 1/adjusted hazard.

152

## 153 **Results**

154

### 155 **Cohort participants and *P. falciparum* infections**

156 This analysis involved data from 477 children and adults (233 males and 244 females)  
157 that were followed for a total of 1339 person-years (Table 1).

158

159

160

161

162

163 **Table 1. Behavioral risk factors for malaria infection and measures of malaria burden in study population, stratified by age**  
 164 **and sex**

165

Metric	Age and gender categories							
	All		< 5 years old		5-15 years old		16 years and older	
	Male	Female	Male	Female	Male	Female	Male	Female
Number of participants, n	233	244	73	84	101	71	59	89
Slept under LLIN the previous night	54.7%	56.3%	54.1%	56.2%	47.9%	47.8%	63.7%	64.3%
Person-years of follow up	324.2	345.4	87.3	96.7	152.6	118.5	84.22	130.1
Number of overnight trips, (incidence*)	44 (0.14)	107 (0.31)	21 (0.24)	19 (0.20)	9 (0.06)	10 (0.08)	14 (0.17)	78 (0.60)
Episodes of malaria**, (incidence*)	11 (0.03)	13 (0.04)	5 (0.06)	2 (0.02)	5 (0.03)	9 (0.08)	1 (0.01)	2 (0.02)
Number of routine visits, n	4,319	4,583	1164	1293	2034	1568	1121	1722
Prevalence of parasitemia by microscopy***	2.9%	1.4%	1.8%	1.1%	4.4%	2.7%	1.3%	0.5%
Prevalence of parasitemia by qPCR	14.4%	9.2%	5.8%	3.7%	17.0%	15.3%	18.5%	7.7%

166 \*per person-year


167 \*\*Malaria includes 1 episode (female, < 5 years old), due to non-falciparum species (*P. malariae*)168 \*\*\*Parasitemia by light microscopy includes 1 episode (female, 5-15 years old) due to non-falciparum species (*P. ovale*)

169

170 149 of 477 participants (31.2%) included in the analysis had at least one *P. falciparum* infection  
171 detected (Figure 1).

172 **Figure 1. Study design.**

173



174  
175 114 participants had 822 successfully genotyped samples and had infections characterized by  
176 clone and by infection event. We achieved a read count of >10,000 for 92% of genotyped  
177 samples, identifying 45 unique AMA-1 haplotypes in our population (frequencies and sequences  
178 in **Supplemental Table 2**). 35 samples had very low-density infections (< 1 parasite/ $\mu$ L) that  
179 could not be genotyped and had infections characterized at the event level only.

180

### 181 **Behavioral malaria risk factors and measures of malaria burden**

182 There was no difference in reported rates of LLIN use the previous night by sex (Table  
183 1). Women over the age of 16 traveled overnight outside of the study area more than men  
184 (incidence rate ratio [IRR] for females vs. males = 3.39, 95% confidence interval [CI] 1.92 to



185 5.99), a potential risk factor for malaria exposure. In this region receiving regular rounds of IRS,  
186 the incidence of symptomatic malaria was low in all age categories, and there was no evidence  
187 of a difference in incidence of symptomatic malaria by sex overall (IRR for females vs. males =  
188 1.14, 95% CI 0.37 to 3.51) or when adjusted for age (IRR = 1.24, 95% CI 0.37 to 4.13). In  
189 contrast, prevalence of *P. falciparum* parasitemia by microscopy was 2.9% in males compared  
190 to 1.4% in females across all age categories (difference of proportions 1.5%, 95% CI 0.87% to  
191 2.1%), with relative differences in prevalence most pronounced in the oldest age group. Similar  
192 findings were seen when prevalence was assessed by ultrasensitive qPCR (14.4% in males vs.  
193 9.2% in females, 95% CI for difference of proportions 3.8% to 6.5%), again with the largest  
194 differences seen in the oldest age group. There was no evidence for differences in parasite  
195 density as determined by qPCR between males and females after adjusting for age as a  
196 continuous variable ( $p = 0.47$ ).

197

### 198 **Force of infection by age and sex**

199 To determine whether higher infection prevalence in males was due to an increased rate  
200 of infection, we used longitudinal genotyping to calculate the force of infection (FOI, number of  
201 new blood stage infections per unit time). Overall, the FOI was low, with new infections  
202 occurring on average less than once every 5 years (Table 2).

203 **Table 2. Molecular force of infection (FOI) by clone and by infection event, stratified by age and sex**

204

Molecular force of infection (FOI)	Sex	Age category			
		All	< 5 years	5-15 years	16 years or older
By clone, ppy* (95% CI)	All	0.17 (0.13-0.23)	0.14 (0.07-0.23)	0.18 (0.08-0.39)	0.19 (0.09-0.44)
	Male	0.18 (0.12-0.28)	0.16 (0.06-0.45)	0.19 (0.12-0.33)	0.21 (0.09-0.48)
	Female	0.16 (0.09-0.30)	0.11 (0.02-0.49)	0.18 (0.08-0.42)	0.18 (0.06-0.54)
By event, ppy* (95% CI)	All	0.14 (0.11-0.18)	0.09 (0.06-0.16)	0.16 (0.08-0.30)	0.16 (0.08-0.32)
	Male	0.16 (0.11-0.22)	0.13 (0.07-0.26)	0.18 (0.12-0.27)	0.15 (0.07-0.15)
	Female	0.13 (0.08-0.21)	0.06 (0.02-0.19)	0.14 (0.07-0.27)	0.18 (0.07-0.43)

205 \*per person-year

206

207 There was no evidence for a significant difference in FOI by sex overall (IRR for females vs.  
208 males = 0.88, 95% CI 0.48 to 1.62 by clone and IRR = 0.83, 95% CI 0.52 to 1.33 by infection  
209 event). There was also no evidence for a significant difference in FOI by sex when adjusted for  
210 age category (IRR = 0.84, 95% CI 0.45 to 1.56 by clone and IRR = 0.79, 95% CI 0.49 to 1.28 by  
211 infection event).

212

### 213 **Rate of clearance of infection and duration of infection by sex**

214 Since females had a lower prevalence of infection but similar rate of acquiring infections  
215 compared to males, we evaluated whether there was a difference between sexes in the rate at  
216 which infections were cleared. Unadjusted hazard ratios for clearing infecting clones showed  
217 that asymptomatic infections cleared naturally (*i.e.*, when not treated by antimalarials) at nearly  
218 twice the rate in females vs. males (hazard ratio (HR) 1.92, 95 % CI 1.19 to 3.11, Table 3). In  
219 addition, new infections cleared faster than baseline infections and monoclonal infections  
220 cleared faster than polyclonal infections. Unadjusted hazard ratios for clearance of infection  
221 events (as opposed to clones) also showed faster clearance in females vs. males (HR = 2.30,  
222 95% CI 1.20 to 4.42).

223 **Table 3. Hazard ratios for rates of clearance of infection, by clone and by infection event**

224

Predictors	Categories	Hazard ratio by clone (95% CI)		Hazard ratio by infection event (95% CI)	
		Unadjusted	Adjusted	Unadjusted	Adjusted
Sex	Male	ref	ref	ref	ref
	Female	1.92 (1.19-3.11)	1.82 (1.20 – 2.75)	2.30 (1.20 – 4.42)	2.07 (1.24 – 3.47)
Age	16 years or greater	ref	ref	ref	ref
	5-15 years	0.66 (0.39 – 1.10)	0.81 (0.49 – 1.36)	0.82 (0.39 – 1.74)	1.27 (0.72 – 2.25)
	< 5 years	1.64 (0.79 – 3.41)	1.55 (0.76 – 3.17)	2.01 (0.80 – 5.00)	1.75 (0.87 – 3.53)
Complexity of infection (COI)	Polyclonal (COI > 1)	ref	--	ref	--
	Monoclonal (COI = 1)	1.63 (1.03 – 2.57)	--	0.95 (0.38 – 2.34)	--
Infection status	Present at baseline	ref	ref	ref	ref
	New infection	1.94 (1.22 – 3.07)	1.75 (1.05 – 2.94)	4.66 (2.58 – 8.42)	4.32 (2.59 – 7.20)
Parasite density *		0.85 (0.69 – 1.06)	0.81 (0.65 – 1.00)	0.41 (0.32 – 0.51)	0.44 (0.35 – 0.54)

225 \*Increasing parasite density (log10) in parasites/microliter, as measured by qPCR

226

227

228 Results were similar in multivariate models including age, gender, the period during  
229 which the infection was first observed, and parasite density, demonstrating faster clearance in  
230 females vs. males (HR =1.82, 95% CI 1.20 to 2.75 by clone and HR =2.07, 95% CI 1.24 to 3.47  
231 by infection event). In both adjusted models, new infections cleared faster than baseline  
232 infections. Higher parasite densities were associated with slower clearance by clone and by  
233 infection event, but the effect size was larger when data were analyzed by infection event (HR =  
234 0.44, 95% CI 0.35 to 0.54). There was no evidence for interaction between age and sex in either  
235 adjusted model.

236 We next estimated durations of asymptomatic infection by age and sex using results  
237 from a model that included these covariates (Figure 2). Durations of infection ranged from 103  
238 days to 447 days by clone, and from 87 to 536 days by infection event. Males had a longer  
239 duration of infection across all age categories. Children aged 5-15 years had the longest  
240 duration of infection, followed by adults. Therefore, overall, males aged 5-15 years had the  
241 longest estimated duration of infection by either clone (447 days) or infection event (526 days).

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257


258

259

260

261 **Figure 2. Estimates of duration of infection from sex- and age-adjusted model**

262  
263  
264



265 Estimated duration of infection in days,  
266 calculated by adjusting the point estimate of the  
267 baseline hazard by coefficients of the sex- and  
268 age-adjusted model. Error bars represent  
269 standard errors of duration obtained from  
270 variance in the model coefficients. Point  
271 estimates of duration are labeled (\*).

## 271 Discussion

272 Previous studies have reported a higher prevalence of malaria infection in males  
273 compared to females, with the difference often ascribed to differences in exposure<sup>5-7</sup>. By closely  
274 following a cohort of children and adults and genotyping every detected infection with sensitive  
275 amplicon deep-sequencing, we were able to estimate both the rate of infection (FOI) and  
276 duration of infection and to compare these measures by sex. We found that lower prevalence in

277 females did not appear to be due to lower rates of infection but rather due to faster clearance of  
278 infections. To our knowledge, this is the first study to report a sex-based difference in the  
279 duration of malaria infection.

280         Many prior studies of malaria incidence and/or prevalence that evaluated associations  
281 with sex in late childhood, adolescence and adulthood have found a male bias in the observed  
282 measure of burden<sup>5–8,29</sup>. Overall, these studies consistently suggest that males exhibit higher  
283 incidence and/or prevalence of malaria that begins during late childhood, persisting through  
284 puberty and the majority of adulthood (excepting the years when pregnancy puts women at  
285 higher risk). One possible explanation put forward for the sex-specific difference in burden has  
286 been that males are more frequently bitten by malaria-carrying mosquitos due to behavioral  
287 differences such as working outside, not sleeping under a net, or traveling for work<sup>6,8–10</sup>. In our  
288 study, however, there were no significant differences in malaria incidence or FOI by sex. We  
289 also saw no evidence of behavioral trends that would result in more infections in males; in fact,  
290 older women in our study did most of the traveling outside the study area (an area of low  
291 transmission compared to surrounding areas). We did not assess work habits as part of our  
292 study questionnaire, but the fact that we observe similar patterns in prevalence by sex in all age  
293 categories makes this a less likely explanation.

294         Very few studies have been conducted to explore immunological differences between  
295 males and females in their response to the malaria parasite. The Garki project found that  
296 females had higher levels of antibodies against *P. falciparum* compared to men<sup>5</sup>. Additionally,  
297 the RTS,S vaccine is associated with higher all-cause mortality in girls compared to boys, and a  
298 trend toward higher risk of fatal malaria was noted in vaccinated girls compared to boys<sup>30</sup>.  
299 Hormonal differences may play a role; studies in mice show that testosterone appears to  
300 downregulate the immune response to malaria<sup>31,32</sup>. More studies are needed to elucidate the  
301 relationship between sex-based biological differences between males and females and their  
302 effects on the development of effective antimalarial immunity.

303           Of the variables we evaluated in addition to sex, baseline infection status and parasite  
304 density were associated with the rate of clearance of infection. Infections that were already  
305 present at the beginning of the study may have been a non-random selection of well-established  
306 asymptomatic infections that were present at baseline at a higher frequency than average  
307 because they had a fundamentally different trajectory than newly established asymptomatic  
308 infections. Higher parasite densities were also associated with slower clearance of infection in  
309 both adjusted models, but the effect was most pronounced when the data were analyzed by  
310 infection event. This may be because low-density infections that we were unable to successfully  
311 genotype were only included in the infection event analysis, and these events tended to have  
312 short durations. The inclusion of parasite density in our multivariate models did not meaningfully  
313 alter associations between sex and duration of infection, providing evidence that the sex-based  
314 differences in duration were not mediated primarily by differences in parasite density in our  
315 cohort.  
316



317 **References**

318

319 1. Bousema T, Okell L, Felger I, Drakeley C. Asymptomatic malaria infections: detectability,  
320 transmissibility and public health relevance. *Nat Rev Microbiol*. 2014;12(12):833–840.

321 2. Okell LC, Bousema T, Griffin JT, Ouédraogo AL, Ghani AC, Drakeley CJ. Factors determining  
322 the occurrence of submicroscopic malaria infections and their relevance for control.  
323 *Nature Communications*. 2012 Dec 4;3(1):1–9.

324 3. Tadesse FG, Slater HC, Chali W, et al. The Relative Contribution of Symptomatic and  
325 Asymptomatic *Plasmodium vivax* and *Plasmodium falciparum* Infections to the Infectious  
326 Reservoir in a Low-Endemic Setting in Ethiopia. *Clin Infect Dis*. 2018 01;66(12):1883–1891.

327 4. Slater HC, Ross A, Felger I, et al. The temporal dynamics and infectiousness of subpatent  
328 *Plasmodium falciparum* infections in relation to parasite density. *Nature Communications*.  
329 2019 Mar 29;10(1):1433.

330 5. Molineaux L, Gramiccia G, Organization WH. The Garki project : research on the  
331 epidemiology and control of malaria in the Sudan savanna of West Africa [Internet]. World  
332 Health Organization; 1980 [cited 2020 Feb 18]. Available from:  
333 <https://apps.who.int/iris/handle/10665/40316>

334 6. Pathak S, Rege M, Gogtay NJ, et al. Age-Dependent Sex Bias in Clinical Malarial Disease in  
335 Hypoendemic Regions. *PLoS One* [Internet]. 2012 Apr 25 [cited 2020 Feb 18];7(4).

- 336 7. Landgraf B, Kollaritsch H, Wiedermann G, Wernsdorfer WH. Parasite density of  
337 *Plasmodium falciparum* malaria in Ghanaian schoolchildren: evidence for influence of sex  
338 hormones? *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1994  
339 Jan;88(1):73–74.
- 340 8. Camargo LMA, Colletto GMDD, Ferreira MU, et al. Hypoendemic Malaria in Rondonia  
341 (Brazil, Western Amazon Region): Seasonal Variation and Risk Groups in an Urban Locality.  
342 *The American Journal of Tropical Medicine and Hygiene*. 1996 Jul 1;55(1):32–38.
- 343 9. Moon JJ, Cho S-Y. Incidence patterns of vivax malaria in civilians residing in a high-risk  
344 county of Kyonggi-do (Province), Republic of Korea. *Korean J Parasitol*. 2001  
345 Dec;39(4):293–299.
- 346 10. Finda MF, Moshi IR, Monroe A, et al. Linking human behaviours and malaria vector biting  
347 risk in south-eastern Tanzania. *PLoS One* [Internet]. 2019 Jun 3 [cited 2020 Apr 8];14(6).
- 348 11. Nhamoyebonde S, Leslie A. Biological Differences Between the Sexes and Susceptibility to  
349 Tuberculosis. *J Infect Dis*. 2014 Jul 15;209(suppl\_3):S100–S106.
- 350 12. Bernin H, Lotter H. Sex Bias in the Outcome of Human Tropical Infectious Diseases:  
351 Influence of Steroid Hormones. *J Infect Dis*. 2014 Jul 15;209(suppl\_3):S107–S113.
- 352 13. Fischer J, Jung N, Robinson N, Lehmann C. Sex differences in immune responses to  
353 infectious diseases. *Infection*. 2015 Aug 1;43(4):399–403.

- 354 14. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. *Nat*  
355 *Rev Immunol.* 2008 Sep;8(9):737–744.
- 356 15. Nankabirwa JI, Briggs J, Rek J, et al. Persistent Parasitemia Despite Dramatic Reduction in  
357 Malaria Incidence After 3 Rounds of Indoor Residual Spraying in Tororo, Uganda. *J Infect*  
358 *Dis.* 2019 Mar 15;219(7):1104–1111.
- 359 16. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive  
360 detection of *Plasmodium falciparum* by amplification of multi-copy subtelomeric targets.  
361 *PLoS Med.* 2015 Mar;12(3):e1001788.
- 362 17. Snounou G, Viriyakosol S, Zhu XP, et al. High sensitivity of detection of human malaria  
363 parasites by the use of nested polymerase chain reaction. *Mol Biochem Parasitol.* 1993  
364 Oct;61(2):315–320.
- 365 18. Miller RH, Hathaway NJ, Kharabora O, et al. A deep sequencing approach to estimate  
366 *Plasmodium falciparum* complexity of infection (COI) and explore apical membrane  
367 antigen 1 diversity. *Malar J.* 2017 Dec 16;16(1):490.
- 368 19. Hathaway NJ, Parobek CM, Juliano JJ, Bailey JA. SeekDeep: single-base resolution de novo  
369 clustering for amplicon deep sequencing. *Nucleic Acids Res.* 2018 Feb 28;46(4):e21–e21.
- 370 20. Lerch A, Koepfli C, Hofmann NE, et al. Longitudinal tracking and quantification of individual  
371 *Plasmodium falciparum* clones in complex infections. *Sci Rep [Internet].* 2019 Mar 4 [cited  
372 2020 Feb 18];9.

- 373 21. Koepfli C, Mueller I. Malaria Epidemiology at the Clone Level. *Trends Parasitol.* 2017  
374 Dec;33(12):974–985.
- 375 22. Nguyen T-N, von Seidlein L, Nguyen T-V, et al. The persistence and oscillations of  
376 submicroscopic *Plasmodium falciparum* and *Plasmodium vivax* infections over time in  
377 Vietnam: an open cohort study. *Lancet Infect Dis.* 2018 May;18(5):565–572.
- 378 23. Koepfli C, Schoepflin S, Bretscher M, et al. How much remains undetected? Probability of  
379 molecular detection of human Plasmodia in the field. *PLoS ONE.* 2011 Apr 28;6(4):e19010.
- 380 24. Ross A, Koepfli C, Li X, et al. Estimating the numbers of malaria infections in blood samples  
381 using high-resolution genotyping data. *PLoS ONE.* 2012;7(8):e42496.
- 382 25. R Core Team. R: A language and environment for statistical computing. [Internet]. R  
383 Foundation for Statistical Computing, Vienna, Austria.; 2019. Available from: URL  
384 <https://www.R-project.org/>.
- 385 26. Python Language Reference, version 3.7.4. [Internet]. Python Software Foundation.;  
386 Available from: Available at <http://www.python.org>
- 387 27. Rondeau V, Gonzalez JR. frailtypack: A computer program for the analysis of correlated  
388 failure time data using penalized likelihood estimation. *Computer Methods and Programs  
389 in Biomedicine.* 2005 Nov 1;80(2):154–164.

- 390 28. Rondeau V, Marzroui Y, Gonzalez JR. frailtypack: An R Package for the Analysis of  
391 Correlated Survival Data with Frailty Models Using Penalized Likelihood Estimation or  
392 Parametrical Estimation. *Journal of Statistical Software*. 2012 Apr 17;47(1):1–28.
- 393 29. Abdalla SI, Malik EM, Ali KM. The burden of malaria in Sudan: incidence, mortality and  
394 disability – adjusted life – years. *Malar J*. 2007 Jul 28;6:97.
- 395 30. Klein SL, Shann F, Moss WJ, Benn CS, Aaby P. RTS,S Malaria Vaccine and Increased  
396 Mortality in Girls. *mBio* [Internet]. 2016 Apr 26 [cited 2020 Feb 18];7(2).
- 397 31. Delić D, Ellinger-Ziegelbauer H, Vohr HW, Dkhil M, Al-Quraishy S, Wunderlich F.  
398 Testosterone response of hepatic gene expression in female mice having acquired  
399 testosterone-unresponsive immunity to *Plasmodium chabaudi* malaria. *Steroids*. 2011  
400 Oct;76(10–11):1204–1212.
- 401 32. Wunderlich F, Marinovski P, Benten WP, Schmitt-Wrede H.P., Mossman, H. Testosterone  
402 and Other Gonadal Factor(s) Restrict the Efficacy of Genes Controlling Resistance to  
403 *Plasmodium Chabaudi* Malaria [Internet]. *Parasite immunology*. 1991 [cited 2020 Feb 18].

404